Clinical Trials
Fostamatinib - IgA Nephropathy:
A Phase 2, multi-center, randomized, double-blind, ascending-dose, placebo-controlled clinical study of fostamatinib disodium in the treatment of IgA Nephropathy (IgAN). The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of IgAN.